ArticlePloS one2020
Prescribing trends of glaucoma drugs in six major cities of China from 2013 to 2017.
Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 27 citations in OpenAlex.
- Branded Compared with Generic Latanoprost in Glaucoma Therapy: Where Do We Stand?Advances in therapy · 2026Review
- Potentially Inappropriate Medication and Associated Factors Among Older Patients with HIV/AIDS: A Multicenter Cross-Sectional Study.Clinical interventions in aging · 2025Article
- Prescribing trends of glaucoma medication in Korea from 2007 to 2020: A nationwide population-based study.PloS one · 2024Article
- Prescribing Trends of Fixed-Dose Combination Antibiotics Not Recommended by the WHO (FNRs) for ICU Patients in Six Major Areas of China During a Seven-Year Period.Drug design, development and therapy · 2024Article
- The Achievement of IOP Target Among a Sample of Iraqi Patients with Glaucoma: A Retrospective Study.Clinical ophthalmology (Auckland, N.Z.) · 2024Article
- [Use of antiglaucomatous drugs in the urban adult population : New Insights into the prevalence of glaucoma from the Hamburg City Health Study].Die Ophthalmologie · 2023Review
- The Multifarious Effects of Various Glaucoma Pharmacotherapy on Corneal Endothelium: A Narrative Review.Ophthalmology and therapy · 2023Review
- KRASJournal of cellular and molecular medicine · 2023Article
- Use Pattern of Ophthalmic Antiglaucoma Agents with and without Preservatives: A Cross-Sectional Study.Pharmaceuticals (Basel, Switzerland) · 2023Article
- The status of TKI/acid-suppressant concomitant use in 44 hospitals in China: A cross-sectional descriptive study.Medicine · 2022Article
- [Glaucoma care in Germany-results of a survey among German ophthalmologists-part 2: treatment].Die Ophthalmologie · 2022Article
- Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand?The British journal of ophthalmology · 2022Review
- Nation-Wide Analysis of Glaucoma Medication Prescription in Fiscal Year of 2019 in Japan.Journal of personalized medicine · 2022Article
- The use of fixed dose drug combinations for glaucoma in clinical settings: a retrospective, observational, single-centre study.International ophthalmology · 2022Observational
- Trends in Outpatient Prescribing Patterns for Ocular Topical Anti-Infectives in Six Major Areas of China, 2013-2019.Antibiotics (Basel, Switzerland) · 2021Article
- Trends in Topical Prescriptional Therapy for Old Patients With Dry Eye Disease in Six Major Areas of China: 2013-2019.Frontiers in pharmacology · 2021Article
- Anti-seizure Medication Prescription in Adult Outpatients With Epilepsy in China, 2013-2018.Frontiers in neurology · 2021Article
- Utilization of Drugs for Attention-Deficit Hyperactivity Disorder Among Young Patients in China, 2010-2019.Frontiers in psychiatry · 2021Article
- Trends in Antidepressant Use and Expenditure in Six Major Cities in China From 2013 to 2018.Frontiers in psychiatry · 2020Article
- Correction: Prescribing trends of glaucoma drugs in six major cities of China from 2013 to 2017.PloS oneArticle
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the prescribing trends of glaucoma drugs in six major cities of China from 2013 to 2017.
methodsA descriptive analysis using pharmacy prescription data was conducted. Outpatient prescription data was extracted from the Hospital Prescription Analysis Cooperative Project. Prescribing patterns, trends of visits, and corresponding expenditures for glaucoma medications were analyzed.
resultsA total of 84297 ambulatory prescriptions were included in the current study. Visits by glaucoma patients increased from 13808 in 2013 to 20060 in 2017. Over the same period, the yearly expenditure for glaucoma drugs increased from 2.33 million to 3.95 million Chinese Yuan (CNY). Among all the six classes of glaucoma drugs (prostaglandin analogues, carbonic anhydrase inhibitors, α-receptor agonists, β-receptor antagonists, cholinergic agonists and fixed combinations), β-receptor antagonists were the most commonly prescribed in 2013, accounting for 34.3% of patients, but gradually decreased to 27.1% in 2017. Prostaglandin analogues became the most frequently prescribed drugs in 2017, accounting for 30.2% of the visits. Prostaglandin analogues are the most expensive and yielded a total expenditure of 2.34 million CNY in 2017, followed by carbonic anhydrase inhibitors, α-receptor agonists, β-receptor antagonists, fixed combinations, and cholinergic agonists. Combination therapy became increasingly prescribed in 2017.
conclusionGlaucoma prescribing practices exhibited substantial changes over the study period. The number of glaucoma prescriptions continuously increased from 2013 to 2017, leading to increased prescription costs. These findings implied a similar trend observed in previous studies, as well as recommendations in the appropriate guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.